Search results for " Real-world evidence"

showing 3 items of 3 documents

Real-life assessment of chronic rhinosinusitis patients using mobile technology: the mySinusitisCoach project by EUFOREA

2020

Abstract Background Chronic rhinosinusitis (CRS) is a chronic inflammatory disease associated with a substantial personal and socioeconomic burden. Monitoring of patient‐reported outcomes by mobile technology offers the possibility to better understand real‐life burden of CRS. Methods This study reports on the cross‐sectional evaluation of data of 626 users of mySinusitisCoach (mSC), a mobile application for CRS patients. Patient characteristics of mSC users were analysed as well as the level of disease control based on VAS global rhinosinusitis symptom score and adapted EPOS criteria. Results The mSC cohort represents a heterogeneous group of CRS patients with a diverse pattern of major sy…

Aplicacions mòbilsSYMPTOMSSinusititsvisual analogue scale0302 clinical medicineQuality of lifeMedicine and Health SciencesImmunology and AllergyNasal polyps030223 otorhinolaryngologyRhinitisnasal polypreal‐world evidenceASSOCIATION3. Good healthPREVALENCEALLERGIC RHINITISpatient-reported outcome measureCohortOriginal Articlepatient‐reported outcome measureENDOSCOPIC SINUS SURGERYmedicine.medical_specialtyVisual analogue scaleImmunologyMobile health technology03 medical and health sciencesNasal PolypsInternal medicinemedicineotorhinolaryngologic diseasesHumansNASALSinusitisreal-world evidenceDisease burdenMobile health technology; nasal polyp; patient-reported outcome measure; real-world evidence; visual analogue scaleTelecommunication in medicineAsthmabusiness.industryRhinitis Sinusitis and Upper Airway DiseaseFunctional endoscopic sinus surgerymedicine.diseasePrecision medicineSEVERITYCross-Sectional Studies030228 respiratory system3121 General medicine internal medicine and other clinical medicineChronic DiseaseMobile appsQuality of LifeASTHMAHuman medicineORIGINAL ARTICLESVISUAL ANALOG SCALEbusinessTelecomunicació en medicina
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression:Healthcare resource utilization

2022

Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"

Healthcare resource utilization Major depressive disorder Observational study Real-world evidence Treatment resistant depressionmedicine.medical_specialtyMajor depressive disorderTreatment resistant depressionCohort StudiesIndirect costsDepressive Disorder Treatment-ResistantHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depressionObservational studyHealth careHealthcare resource utilizationmedicineHumansMajor depressive episodeDepression (differential diagnoses)Retrospective StudiesReal-world evidenceDepressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajorHealth Care Costsmedicine.diseasePsychiatry and Mental healthClinical PsychologyEmergency medicineMajor depressive disorderObservational studymedicine.symptombusinessHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depression; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Retrospective Studies; Depressive Disorder Major; Depressive Disorder Treatment-ResistantTreatment-resistant depressionDelivery of Health CareCohort study
researchProduct

Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.

2022

Abstract Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentEffectivenessYoung AdultInternal medicineAdalimumabMedicineHumansAdverse effectskin and connective tissue diseasesColectomyColectomyAgedRetrospective StudiesReal-world evidenceHepatologybusiness.industryGastroenterologyEffectiveneAdalimumabRetrospective cohort studyInduction ChemotherapyMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuationClinical PracticeTreatment OutcomeUlcerative colitisItalyAdalimumab; Effectiveness; Real-world evidence; Safety; Ulcerative colitisConcomitantColitis UlcerativeFemaleTumor Necrosis Factor InhibitorsSafetybusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct